• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Gabapentin Improve Sexual Function in Women with Vulvodynia?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The original trial by this study team did not find a significant improvement with gabapentin (determined by the tampon test) in women with localized provoked vulvodynia (PVD)
  • Bachmann et al. (AJOG, 2019) performed a secondary analysis to determine whether extended-release gabapentin was effective in improving sexual function in women with PVD

METHODS:

  • Secondary outcome of a multicenter double-blind, randomized crossover trial (RCT)
    • Patients with localized PVD, formally known as vulvar vestibulitis
    • 18-week time frame
    • 6 weeks per treatment period
      • 4-week dose titration | 2-week maintenance dose | 4-day washout period
    • Patients received either
      • Gabapentin (1200 to 3000 mg/d)
      • Placebo
    • Outcomes assessed
      • Sexual function, measured by FSFI
      • Stratified based on baseline provoked pelvic muscle pain severity scores
    • 56 pain-free control subjects, matched by age and race, also completed Female Sexual Function Index (FSFI) for comparison to determine if sexual function in women with PVD would be similar either before or after treatment

RESULTS:

  • 230 women were screened at 3 academic institutions
    • 89 participants
  • Gabapentin was more effective than placebo in improving
    • Overall sexual function: Adjusted mean difference (MD) 1.3 (95% CI, 0.4-2.2; P=.008)
    • Desire: MD 0.2 (95% CI, 0.0-3.3; P=.04)
    • Arousal: MD 0.3 (95% CI, 0.1-0.5; P=.004)
    • Satisfaction: MD 0.3 (95% CI, 0.04-0.5; P=.02)
  • Despite improvement, function remained significantly lower than matched vulvodynia pain-free control subjects
  • No improvement seen for orgasm, lubrication, or pain domains
  • Gabapentin improved outcomes in women with high but not low pelvic muscle pain severity scores
    • Full Female Sexual Function Index scale: MD 1.6 (95% CI, 0.3-2.8; P=.02)
    • Arousal: MD 0.3 (95% confidence interval, 0.1-0.6; P=.01)
    • Pain domain scores did not reach statistical significance (P=.04)

CONCLUSION:

  • Gabapentin improved sexual function in women with provoked vulvodynia, particularly those with increased pelvic muscle pain on exam
  • However, overall sexual function remained lower than women without the disorder

Learn More – Primary Sources:

Effect of gabapentin on sexual function in vulvodynia: a randomized, placebo-controlled trial.

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Is Gabapentin an Effective First Line Drug for Vulvodynia?
Evaluating Vulvodynia – Making the Diagnosis and Key Management Points

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site